This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Besier, S.
Right arrow Articles by Wichelhaus, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Besier, S.
Right arrow Articles by Wichelhaus, T. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1570-1572, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01098-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances{triangledown}

Silke Besier, Albrecht Ludwig, Johannes Zander, Volker Brade, and Thomas A. Wichelhaus*

Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany

Received 21 August 2007/ Returned for modification 24 September 2007/ Accepted 15 January 2008

Linezolid resistance in Staphylococcus aureus is typically associated with mutations in the 23S rRNA gene. Here we show that the accumulation of a single point mutation, G2576T, in the different copies of this gene causes stepwise increases in resistance, impairment of the biological fitness, and cross-resistance to quinupristin-dalfopristin and chloramphenicol.

* Corresponding author. Mailing address: Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Klinikum der J. W. Goethe-Universität, Paul-Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Phone: 49 69 6301 6438. Fax: 49 69 6301 5767. E-mail: Wichelhaus{at}em.uni-frankfurt.de

{triangledown} Published ahead of print on 22 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1570-1572, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01098-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sierra, J. M., Ortega, M., Tarrago, C., Albet, C., Vila, J., Terencio, J., Guglietta, A. (2009). Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant. J Antimicrob Chemother 64: 990-992 [Abstract] [Full Text]  
  • Feng, J., Lupien, A., Gingras, H., Wasserscheid, J., Dewar, K., Legare, D., Ouellette, M. (2009). Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19: 1214-1223 [Abstract] [Full Text]  
  • Foucault, M.-L., Courvalin, P., Grillot-Courvalin, C. (2009). Fitness Cost of VanA-Type Vancomycin Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2354-2359 [Abstract] [Full Text]  
  • Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., Zurenko, G. (2008). In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains. Antimicrob. Agents Chemother. 52: 4442-4447 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»